18482223. HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE simplified abstract (The Board of Trustees of the Leland Stanford Junior University)

HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE

Organization Name

The Board of Trustees of the Leland Stanford Junior University

Inventor(s)

Aaron Michael Ring of New Haven CT (US)

Andrew Kruse of Chestnut Hill MA (US)

Aashish Manglik of Menlo Park CA (US)

Irving L. Weissman of Stanford CA (US)

Roy Louis Maute of San Francisco CA (US)

Melissa N. Mccracken of Boston MA (US)

Sydney Gordon of Stanford CA (US)

HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18482223 titled 'HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE

Simplified Explanation

High affinity PD-1 mimic polypeptides are provided in this patent application, which have an increased affinity for PD-L1 compared to the wild-type protein. These polypeptides can modulate the activity of immune cells in a mammal by blocking the binding interaction between PD-1 and its ligands PD-L1 and/or PD-L2.

• Increased affinity for PD-L1 compared to wild-type PD-1 protein
• Modulates immune cell activity by blocking PD-1 and its ligands

Potential Applications

The technology can be applied in cancer immunotherapy, autoimmune disease treatment, and organ transplantation.

Problems Solved

This technology addresses the need for more effective immune cell modulation in various diseases and conditions.

Benefits

The high affinity PD-1 mimic polypeptides offer a more targeted and potent approach to modulating immune responses, potentially leading to improved treatment outcomes.

Potential Commercial Applications

The technology could be used in pharmaceuticals for cancer treatment, autoimmune disease therapies, and transplant medicine.

Possible Prior Art

Prior art may include existing PD-1 inhibitors or other immunomodulatory therapies that target the PD-1/PD-L1 pathway.

How does the increased affinity of the PD-1 mimic polypeptides for PD-L1 impact their effectiveness in modulating immune cell activity?

The increased affinity allows the polypeptides to more effectively block the binding interaction between PD-1 and PD-L1, leading to enhanced modulation of immune responses.

What are the potential side effects or drawbacks of using high affinity PD-1 mimic polypeptides in modulating immune cell activity?

Potential side effects may include off-target immune responses or autoimmune reactions due to the potent inhibition of the PD-1/PD-L1 pathway. Further studies are needed to assess the safety profile of these polypeptides in clinical settings.

Original Abstract Submitted

High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.